Geode Capital Management LLC Has $3.24 Billion Stock Holdings in Pfizer Inc. $PFE

Key Points

• Geode Capital Management increased its Pfizer stake by 0.9% in the fourth quarter, ending with 130.2 million shares valued at about $3.24 billion. That made Pfizer roughly 2.29% of Geode’s portfolio.
• Pfizer recently beat first-quarter expectations, reporting $0.75 EPS on $14.45 billion in revenue, both above estimates. The company also reaffirmed growth efforts through new late-stage trials, including programs in infant pneumococcal vaccines and obesity treatment.
• Analysts remain mixed but generally constructive: the stock has a consensus Hold rating with an average price target of $28.61, while several firms recently raised targets or upgraded shares. Pfizer also announced a quarterly dividend of $0.43 per share, implying a 6.6% yield.

Geode Capital Management LLC increased its holdings in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 0.9% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 130,192,081 shares of the biopharmaceutical company's stock after buying an additional 1,184,728 shares during the period. Geode Capital Management LLC owned about 2.29% of Pfizer worth $3,235,642,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. Kepler Cheuvreux Suisse SA purchased a new position in shares of Pfizer in the 3rd quarter worth about $16,613,000. Money Concepts Capital Corp boosted its holdings in shares of Pfizer by 29.9% in the 3rd quarter. Money Concepts Capital Corp now owns 248,251 shares of the biopharmaceutical company's stock worth $6,325,000 after buying an additional 57,188 shares during the last quarter. Penn Davis Mcfarland Inc. boosted its holdings in shares of Pfizer by 50.9% in the 4th quarter. Penn Davis Mcfarland Inc. now owns 171,332 shares of the biopharmaceutical company's stock worth $4,266,000 after buying an additional 57,777 shares during the last quarter. Mackenzie Financial Corp boosted its holdings in shares of Pfizer by 119.6% in the 3rd quarter. Mackenzie Financial Corp now owns 3,106,644 shares of the biopharmaceutical company's stock worth $79,157,000 after buying an additional 1,691,773 shares during the last quarter. Finally, Pzena Investment Management LLC boosted its holdings in shares of Pfizer by 0.9% in the 3rd quarter. Pzena Investment Management LLC now owns 6,615,598 shares of the biopharmaceutical company's stock worth $168,565,000 after buying an additional 56,484 shares during the last quarter. Institutional investors own 68.36% of the company's stock.

More Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer announced new late-stage trial activity for its infant pneumococcal vaccine and obesity drug berobenatide, reinforcing that the company is pushing to build future growth drivers beyond its aging portfolio. Pfizer’s Next-Gen Infant Pneumococcal Vaccine Trial: What Investors Should Watch Now
• Positive Sentiment: BofA Securities raised its price target on Pfizer to $27 from $26 after strong first-quarter results and improved 2026 revenue/EPS estimates, signaling continued analyst confidence in the stock’s valuation. BofA Raises Price Target on Pfizer (PFE) Following Strong Q1 Results
• Positive Sentiment: Pfizer is also highlighting its obesity push with a new Phase 3 trial, which could add another major opportunity if results are favorable. Pfizer Steps Up Obesity Push With New Phase 3 Berobenatide Trial
• Neutral Sentiment: Recent commentary says Pfizer is leaning on new launches, Seagen assets, and pipeline progress to offset looming loss-of-exclusivity pressure, but the patent cliff through 2030 remains a major overhang for investors. Pfizer Bets on New & Acquired Drugs to Offset Its LOE Pressure?
• Negative Sentiment: Broader industry coverage on the Eliquis patent cliff underscores the kind of revenue loss Pfizer and peers can face when exclusivity ends, keeping attention on the company’s future replacement pipeline. Thinning revenues: inside the $14bn Eliquis patent cliff

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on PFE shares. HSBC boosted their price objective on Pfizer from $29.00 to $32.00 and gave the company a "buy" rating in a research note on Tuesday, March 17th. BMO Capital Markets restated an "outperform" rating and issued a $30.00 price objective on shares of Pfizer in a research note on Monday, March 9th. Barclays started coverage on Pfizer in a research note on Thursday, February 19th. They issued an "underweight" rating and a $25.00 price objective on the stock. CICC Research started coverage on Pfizer in a research note on Thursday, April 16th. They issued an "outperform" rating and a $33.00 price objective on the stock. Finally, Argus upgraded Pfizer from a "hold" rating to a "buy" rating and set a $35.00 price objective on the stock in a research note on Monday, March 2nd. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, twelve have issued a Hold rating and three have assigned a Sell rating to the stock. Based on data from MarketBeat, Pfizer presently has a consensus rating of "Hold" and an average target price of $28.61.

Pfizer Stock Up 1.5%

PFE stock opened at $26.24 on Thursday. The company has a current ratio of 1.25, a quick ratio of 0.94 and a debt-to-equity ratio of 0.67. The company's 50 day moving average is $26.82 and its 200 day moving average is $26.27. The stock has a market cap of $149.55 billion, a price-to-earnings ratio of 20.03 and a beta of 0.35. Pfizer Inc. has a 1-year low of $23.06 and a 1-year high of $28.75.

Pfizer (NYSE:PFE - Get Free Report) last issued its earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.72 by $0.03. The business had revenue of $14.45 billion during the quarter, compared to analyst estimates of $13.84 billion. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.Pfizer's revenue for the quarter was up 5.4% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.92 earnings per share. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Sell-side analysts predict that Pfizer Inc. will post 2.99 EPS for the current fiscal year.

Pfizer Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 12th. Stockholders of record on Friday, May 8th will be paid a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.6%. The ex-dividend date of this dividend is Friday, May 8th. Pfizer's dividend payout ratio is 131.30%.

Pfizer Profile

Pfizer Inc NYSE: PFE is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer's portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.